HCAT News and Press, Health Catalyst Inc From 05/09/24

SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended March 31, 2024. “For the...

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

2024-05-08 17:35:54 ET More on Health Catalyst Health Catalyst: Achieving FY28 Long-Term Guidance Is Possible Health Catalyst, Inc. (HCAT) Q4 2023 Earnings Call Transcript Health Catalyst Looks To Slim Down As It Faces Industry Headwinds (Downgrade) R1 RCM, H...

SALT LAKE CITY, April 24, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its first quarter 2024 operating results on Thursday, May 9, 2024, after market cl...

2024-04-12 17:05:37 ET Gainers: Applied Optoelectronics ( AAOI ) +5% . Eliem Therapeutics ( ELYM ) +4% . Infinera Corporation ( INFN ) +4% . Harrow ( HROW ) +4% . Health Catalyst ( HCAT ) +4% . Losers: Eagle Pharmaceutica...

2024-04-12 02:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-10 12:56:01 ET More on Certara, GoodRx Holdings, etc. GoodRx Holdings: Large TAM Continues To Support Growth Health Catalyst: Achieving FY28 Long-Term Guidance Is Possible Voss Capital - R1 RCM Inc.: Bull Case Achievable Despite Negative Sentiment Wel...

2024-04-10 06:15:02 ET KeyBanc analyst issues SECTOR WEIGHT recommendation for HCAT on April 10, 2024 04:37AM ET. The previous analyst recommendation was Overweight. HCAT was trading at $6.68 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-03-23 03:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-09 04:50:41 ET Summary Health Catalyst reported strong Q4 results, meeting guidance and showing growth in technology and professional services revenue. The drop in HCAT's share price presents a buying opportunity, as the company's growth initiatives, such as its TEMS offer...